Engineered Fc based antibody domains and fragments as novel scaffolds

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1844, Issue 11, 2014, Pages 1977-1982

  Ying, Tianlei ^a   Gong, Rui ^b   Ju, Tina W ^a   Prabakaran, Ponraj ^a,c   Dimitrov, Dimiter S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WUHAN INSTITUTE OF VIROLOGY   (China)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Antibody engineering; CH2 domain; CH3 domain; Domain antibody; Monoclonal antibody; Monomeric Fc

Indexed keywords

BEVACIZUMAB; DIMER; FC ANTIBODY; FC RECEPTOR; FC RECEPTOR CH2; FC RECEPTOR CH3; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY; MONOMER; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY LIBRARY; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; CYTOTOXICITY; DIMERIZATION; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; STEREOSPECIFICITY;

EID: 84907946136     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2014.04.018     Document Type: Review

References (51)

1. J.M. Reichert Marketed therapeutic antibodies compendium mAbs 4 2012 413 415
2. J.M. Reichert Antibodies to watch in 2014 mAbs 6 2013
3. R.K. Jain Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors Cancer Res. 50 1990 814s 819s
4. A.F. Labrijn, P. Poignard, A. Raja, M.B. Zwick, K. Delgado, M. Franti, J. Binley, V. Vivona, C. Grundner, C.C. Huang, M. Venturi, C.J. Petropoulos, T. Wrin, D.S. Dimitrov, J. Robinson, P.D. Kwong, R.T. Wyatt, J. Sodroski, and D.R. Burton Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1 J. Virol. 77 2003 10557 10565
5. W. Chen, Z. Zhu, Y. Feng, and D.S. Dimitrov Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers Proc. Natl. Acad. Sci. U. S. A. 105 2008 17121 17126
6. L.J. Holt, C. Herring, L.S. Jespers, B.P. Woolven, and I.M. Tomlinson Domain antibodies: proteins for therapy Trends Biotechnol. 21 2003 484 490
7. D. Saerens, G.H. Ghassabeh, and S. Muyldermans Single-domain antibodies as building blocks for novel therapeutics Curr. Opin. Pharmacol. 8 2008 600 608
8. A.L. Nelson, and J.M. Reichert Development trends for therapeutic antibody fragments Nat. Biotechnol. 27 2009 331 337
9. R.E. Kontermann Strategies to extend plasma half-lives of recombinant antibodies BioDrugs 23 2009 93 109
10. N.E. Simister, and K.E. Mostov An Fc receptor structurally related to MHC class I antigens Nature 337 1989 184 187
11. D.C. Roopenian, and S. Akilesh FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 7 2007 715 725
12. T. Ying, W. Chen, Y. Feng, Y. Wang, R. Gong, and D.S. Dimitrov Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics J. Biol. Chem. 288 2013 25154 25164
13. D.S. Dimitrov Engineered CH2 domains (nanoantibodies) mAbs 1 2009 26 28
14. R. Gong, Y. Wang, Y. Feng, Q. Zhao, and D.S. Dimitrov Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor J. Biol. Chem. 286 2011 27288 27293
15. G. Wozniak-Knopp, S. Bartl, A. Bauer, M. Mostageer, M. Woisetschlager, B. Antes, K. Ettl, M. Kainer, G. Weberhofer, S. Wiederkum, G. Himmler, G.C. Mudde, and F. Ruker Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties Protein Eng. Des. Sel. 23 2010 289 297
16. M.W. Traxlmayr, E. Lobner, B. Antes, M. Kainer, S. Wiederkum, C. Hasenhindl, G. Stadlmayr, F. Ruker, M. Woisetschlager, K. Moulder, and C. Obinger Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display Protein Eng. Des. Sel. 26 2013 255 265
17. T. Ying, W. Chen, R. Gong, Y. Feng, and D.S. Dimitrov Soluble monomeric IgG1 Fc J. Biol. Chem. 287 2012 19399 19408
18. E. Alamyar, V. Giudicelli, P. Duroux, and M.P. Lefranc Antibody V and C domain sequence, structure, and interaction analysis with special reference to IMGT((R)) Methods Mol. Biol. 1131 2014 337 381
19. X. Xiao, Y. Feng, B.K. Vu, R. Ishima, and D.S. Dimitrov A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors Biochem. Biophys. Res. Commun. 387 2009 387 392
20. T. Hofer, J.D. Thomas, T.R. Burke Jr., and C. Rader An engineered selenocysteine defines a unique class of antibody derivatives Proc. Natl. Acad. Sci. U. S. A. 105 2008 12451 12456
21. J. Xiao, R. Chen, M.A. Pawlicki, and T.J. Tolbert Targeting a homogeneously glycosylated antibody Fc to bind cancer cells using a synthetic receptor ligand J. Am. Chem. Soc. 131 2009 13616 13618
22. M.J. Chiang, M.A. Holbert, J.H. Kalin, Y.H. Ahn, J. Giddens, M.N. Amin, M.S. Taylor, S.L. Collins, Y. Chan-Li, A. Waickman, P.Y. Hsiao, D. Bolduc, D.J. Leahy, M.R. Horton, L.X. Wang, J.D. Powell, and P.A. Cole An Fc domain protein-small molecule conjugate as an enhanced immunomodulator J. Am. Chem. Soc. 136 2014 3370 3373
23. C. Rader Chemically programmed antibodies Trends Biotechnol. 32 2014 186 197
24. P.J. Carter Potent antibody therapeutics by design, nature reviews Immunology 6 2006 343 357
25. L.G. Presta Molecular engineering and design of therapeutic antibodies Curr. Opin. Immunol. 20 2008 460 470
26. R. Jefferis Antibody therapeutics: isotype and glycoform selection Expert. Opin. Biol. Ther. 7 2007 1401 1413
27. P. Bruhns, B. Iannascoli, P. England, D.A. Mancardi, N. Fernandez, S. Jorieux, and M. Daeron Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses Blood 113 2009 3716 3725
28. R.L. Shields, A.K. Namenuk, K. Hong, Y.G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, J.A. Fox, and L.G. Presta High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R J. Biol. Chem. 276 2001 6591 6604
29. R.L. Shields, J. Lai, R. Keck, L.Y. O'Connell, K. Hong, Y.G. Meng, S.H. Weikert, and L.G. Presta Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity J. Biol. Chem. 277 2002 26733 26740
30. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat. Med. 6 2000 443 446
31. G.A. Lazar, W. Dang, S. Karki, O. Vafa, J.S. Peng, L. Hyun, C. Chan, H.S. Chung, A. Eivazi, S.C. Yoder, J. Vielmetter, D.F. Carmichael, R.J. Hayes, and B.I. Dahiyat Engineered antibody Fc variants with enhanced effector function Proc. Natl. Acad. Sci. U. S. A. 103 2006 4005 4010
32. S.Y. Chu, I. Vostiar, S. Karki, G.L. Moore, G.A. Lazar, E. Pong, P.F. Joyce, D.E. Szymkowski, and J.R. Desjarlais Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies Mol. Immunol. 45 2008 3926 3933
33. M.S. Hayden-Ledbetter, C.G. Cerveny, E. Espling, W.A. Brady, L.S. Grosmaire, P. Tan, R. Bader, S. Slater, C.A. Nilsson, D.S. Barone, A. Simon, C. Bradley, P.A. Thompson, A.F. Wahl, and J.A. Ledbetter CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells Clin. Cancer Res. 15 2009 2739 2746
34. P.M. Davis, R. Abraham, L. Xu, S.G. Nadler, and S.J. Suchard Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity J. Rheumatol. 34 2007 2204 2210
35. Y. Wang, Z. Tian, D. Thirumalai, and X. Zhang Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering J. Drug Target. 2014
36. W.F. Dall'Acqua, R.M. Woods, E.S. Ward, S.R. Palaszynski, N.K. Patel, Y.A. Brewah, H. Wu, P.A. Kiener, and S. Langermann Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences J. Immunol. 169 2002 5171 5180
37. J. Zalevsky, A.K. Chamberlain, H.M. Horton, S. Karki, I.W. Leung, T.J. Sproule, G.A. Lazar, D.C. Roopenian, and J.R. Desjarlais Enhanced antibody half-life improves in vivo activity Nat. Biotechnol. 28 2010 157 159
38. M. Jain, N. Kamal, and S.K. Batra Engineering antibodies for clinical applications Trends Biotechnol. 25 2007 307 316
39. G. Wozniak-Knopp, J. Stadlmann, and F. Ruker Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds PLoS ONE 7 2012 e30083
40. M.J. Feige, S. Walter, and J. Buchner Folding mechanism of the CH2 antibody domain J. Mol. Biol. 344 2004 107 118
41. R. Gong, B.K. Vu, Y. Feng, D.A. Prieto, M.A. Dyba, J.D. Walsh, P. Prabakaran, T.D. Veenstra, S.G. Tarasov, R. Ishima, and D.S. Dimitrov Engineered human antibody constant domains with increased stability J. Biol. Chem. 284 2009 14203 14210
42. P. Prabakaran, B.K. Vu, J. Gan, Y. Feng, D.S. Dimitrov, and X. Ji Structure of an isolated unglycosylated antibody C(H)2 domain Acta Crystallogr. D Biol. Crystallogr. 64 2008 1062 1067
43. R. Gong, W. Chen, and D.S. Dimitrov Candidate antibody-based therapeutics against HIV-1 BioDrugs 26 2012 143 162
44. R. Gong, and G. Xiao Engineered antibody variable and constant domains as therapeutic candidates Pharm. Pat. Anal. 2 2013 637 646
45. B.J. Hackel, A. Kapila, and K.D. Wittrup Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling J. Mol. Biol. 381 2008 1238 1252
46. R. Gong, Y. Wang, T. Ying, Y. Feng, E. Streaker, P. Prabakaran, and D.S. Dimitrov N-terminal truncation of an isolated human IgG1 CH2 domain significantly increases its stability and aggregation resistance Mol. Pharm. 10 2013 2642 2652
47. K. Gehlsen, R. Gong, D. Bramhill, D. Wiersma, S. Kirkpatrick, Y. Wang, Y. Feng, and D.S. Dimitrov Pharmacokinetics of engineered human monomeric and dimeric CH2 domains mAbs 4 2012 466 474
48. R. Gong, Y. Wang, T. Ying, and D.S. Dimitrov Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn PLoS ONE 7 2012 e42288
49. R. Rouet, D. Lowe, and D. Christ Stability engineering of the human antibody repertoire FEBS Lett. 588 2014 269 277
50. J.M. Perchiacca, and P.M. Tessier Engineering aggregation-resistant antibodies Ann. Rev. Chem. Biomol. Eng. 3 2012 263 286
51. W. Chen, R. Gong, T. Ying, P. Prabakaran, Z. Zhu, Y. Feng, and D.S. Dimitrov Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains Curr. Drug Discov. Technol. 11 2014 28 40